Is Distillate Small/Mid Cash Flow ETF (DSMC) a Buy, Sell, or Hold?
NYSE : DSMC
Distillate Small/Mid Cash Flow ETF
$41.855 USD
-$0.32 (-0.75%)
- Volume
- 3.91K
- Average Volume
- 5.72K
- Market Capitalization
- $131.67M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- Year High
- $42.26
- Year Low
- $32.55
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
| Source | Headline |
|---|---|
|
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four previously completed clinical trials – – All active patients in the treatment arm have reached their second DURAVYU dosing visit, with over 35% receiving a third dose – WATERTOWN, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the independent Data Safety Monitoring Committee (DSMC) completed its third scheduled review of the Company's pivotal Phase 3 program evaluating DURAVYU for wet age-related macular degeneration (wet AMD) and recommended that both the LUGANO and LUCIA trials continue as planned with no protocol modifications. globenewswire.com - 2026-05-14 07:00:00 |
